Sequenom, Inc. Announces Issuance Of Patent For Methods Of Detecting Fetal
SAN DIEGO, Dec. 6, 2012
SAN DIEGO, Dec. 6, 2012 /PRNewswire/ --Sequenom, Inc. (NASDAQ: SQNM), a life
sciences company providing innovative genetic analysis solutions, today
announced that the U.S. Patent and Trademark Office will issue U.S. Patent No.
8,340,916 on December 25, 2012 with claims to novel methods for detecting
fetal aneuploidy using massively parallel sequencing.The patent is entitled
Diagnosing Fetal Chromosomal Aneuploidy Using Massively Parallel Genomic
Sequencing and was invented by Drs. Dennis Lo, Rossa Chiu and Alan Chan of the
Chinese University of Hong Kong.Sequenom has exclusive rights to this patent.
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to
improving healthcare through revolutionary genetic analysis solutions.
Sequenom develops innovative technology, products and diagnostic tests that
target and serve discovery and clinical research, and molecular diagnostics
markets. The company was founded in 1994 and is headquartered in San Diego,
California. Sequenom maintains a Web site at www.sequenom.comto which
Sequenom regularly posts copies of its press releases as well as additional
information about Sequenom. Interested persons can subscribe on the Sequenom
Web site to email alerts or RSS feeds that are sent automatically when
Sequenom issues press releases, files its reports with the Securities and
Exchange Commission or posts certain other information to the Web site.
Except for the historical information contained herein, the matters set forth
in this press release, including statements regarding the Company's commitment
to improving healthcare through revolutionary genetic analysis solutions, are
forward-looking statements within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are subject to risks and uncertainties that may cause actual
results to differ materially, including the risks and uncertainties associated
with market demand for and acceptance and use by customers of its products,
reliance upon the collaborative efforts of other parties, the Company's
financial position, its ability to position itself for product launches and
growth and develop and commercialize new technologies and products,
particularly newer technologies such as noninvasive prenatal diagnostics,
laboratory developed tests, and genetic analysis platforms, the Company's
ability to manage its existing cash resources or raise additional cash
resources, competition, intellectual property protection and intellectual
property rights of others, government regulation particularly with respect to
diagnostic products and laboratory developed tests, obtaining or maintaining
regulatory approvals, litigation involving the Company, and other risks
detailed from time to time in the Company's most recently filed Quarterly
Report on Form 10-Q and Annual Report on Form 10-K for the year ended December
31, 2011, and other documents subsequently filed with or furnished to the
Securities and Exchange Commission. These forward-looking statements are based
on current information that may change and you are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of the
date of this press release. All forward-looking statements are qualified in
their entirety by this cautionary statement, and the Company undertakes no
obligation to revise or update any forward-looking statement to reflect events
or circumstances after the issuance of this press release.
SOURCE Sequenom, Inc.
Contact: Marcy Graham, Senior Director, Investor Relations & Corp Comm,
Sequenom, Inc., +1-858-202-9028, email@example.com; or Jakob Jakobsen,
Media Contact, Chandler Chicco Agency, +1-310-309-1003,
Press spacebar to pause and continue. Press esc to stop.